ASCO® 2026 Highlights: Presenter Vignette – Zhonglin Hao

Dr. Zhonglin Hao

Zhonglin Hao

MD, PhD

Markey Cancer Center

8012

Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC.